Navigation Links
CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
Date:3/24/2008

's Hospital, performed the first CryoValve SG implant surgery since FDA clearance of the product in a patient who had undergone two previous allograft implants.

"The new technology provided by this SynerGraft processing was used in this patient in an effort to limit additional valve operations," said Dr. Huddleston. "We are very hopeful that this new valve will be a great thing for the patient and that the outcome with the CryoValve SG implant will last longer than the previous valve surgeries."

At the FDA's request, CryoLife is planning a post-clearance study to seek evidence for the potential and implied long-term benefits of the SynerGraft process. Data to be collected is expected to include long-term safety and hemodynamic function, immune response and explant analysis. CryoLife believes that this information may help it ascertain whether the SynerGraft process reduces the immunogenicity or potential for rejection of the transplanted heart valve and whether the valve recellularizes with the recipients own cells.

Please visit the CryoLife website at http://www.cryolife.com for additional information about the SynerGraft technology and CryoValve SG.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart v
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
2. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
3. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
4. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
5. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
6. CryoLife Announces Record Preservation Services and Product Revenues for 2007
7. CryoLife to Present at OneMedPlace Finance Forum
8. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
9. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
10. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
11. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... NEW YORK, March 1, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0788386/Global-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno The global outlook series ... anecdotes, market briefs, and concise summaries of ...
... 2012  Receptos Inc. today announced that the company is scheduled ... Care Conference at noon EST on Wednesday, March 7, 2012, ... Hasnain, president and chief executive officer, will provide an overview ... programs. "This is an exciting time at ...
... Laboratories, Inc. (OTCBB: UGNE), a leader in the design, ... that the Company,s senior management team will host a ... 8, 2012 at 11 a.m. ET to discuss fourth ... Interested participants and investors may access the conference call ...
Cached Biology Technology:Global Biotechnology Industry 2Global Biotechnology Industry 3Global Biotechnology Industry 4Global Biotechnology Industry 5Global Biotechnology Industry 6Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2
(Date:4/23/2014)... "playwright" to their resumes in an effort to aid ... ethical issues as genomic science transitions to bedside healthcare, ... , Until now the plays of Karen H. ... and by, their peers and others in the genomics ... With Oxford University Press, publication of the book ...
(Date:4/23/2014)... is available in French and German . ... female? In humans and other mammals, the difference between sexes depends ... is present only in males, where the two sexual chromosomes are ... Y is ultimately responsible for all the morphological and physiological differences ... the case. A very long time ago, the X and Y ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Male or female? 2Male or female? 3On the defensive 2On the defensive 3
... nanometer and micron size scales could play a key ... improve the reliability, reduce the size and lower the ... by a team of scientists from the Georgia Tech ... the Naval Surface Warfare Center, the highly-uniform copper structures ...
... treat certain cancers and rheumatoid arthritis appears to greatly ... Medicine researchers report in the Journal of Clinical Investigation. ... continue to be observed long after the antibody is ... antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in ...
... or physical disabilities should not resort to a ... University. Lori Marino, senior lecturer in the Neuroscience ... Lilienfeld, professor in the Department of Psychology, to ... purveyors of what is known as dolphin-assisted therapy ...
Cached Biology News:Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3Cancer and arthritis therapy may be promising treatment for diabetes 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 3
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... designed for use with the ProQuest Two-Hybrid ... contains deletions in the endogenous GAL4 and ... systems. The strain also has leu2 and ... and prey vectors. MaV203 contains three GAL4 ...
Request Info...
Biology Products: